Brain-Derived Neurotrophic Factor (BDNF) and First-Episode Psychosis. A longitudinal one-year prognosis study.

The brain-derived neurotrophic factor (BDNF) is a neurotrophin that has been linked to the schizophrenia neurodevelopmental hypothesis.

DELAYED NEUROPSYCHIATRIC SYNDROME AFTER CARBON MONOXIDE POISONING.

arbon monoxide (CO) is an odorless, tasteless, colorless and nonirritating gas 1. In Spain, most of the accidents due to CO poisoning are caused by water heaters2,3,4. CO binds to hemoglobin with much greater affinity than oxygen, for- ming carboxyhemoglobin (COHb) and resulting in impaired oxygen transport and utilization.XS In up to 40 percent of patients with significant CO exposure, a delayed neuropsy- chiatric syndrome (DNS) can arise 3 to 240 days after appa- rent recovery, characterized by cognitive deficits, personality changes, movement disorders, and focal neurologic deficits, which may persist for a year or longer.

Chronotype as modulator of morning serum melatonin levels.

BACKGROUND: The search for biological markers of individual characteristics has produced scanty results. Melatonin (MLT), the main hormonal product of the pineal gland, has been used as a biological marker of neuroticism, introversion-extroversion and morningness-eveningness. Morningness-eveningness indicates preferences associated with morning or evening activities. The goal of this research is to study if serum MLT levels are related to morningness-eveningness preference. METHODS: Twenty-three morning type and twenty-one evening type healthy volunteers took part in the study. Morningness-eveningness was evaluated with the Composite Scale of Morningness. Blood was drawn at 09:00, 12:00 and 00:00 h. MLT levels were measured with an ELISA. RESULTS: At 09:00 h evening type subjects had significantly higher serum MLT levels than morning type subjects (8.4±3.6 pg./ml. vs. 4.6±3.2 pg./ml., p<0.02). CONCLUSIONS: Morning serum MLT may be used as a biological peripheral marker of morningness-eveningness preference. Our results emphasise the convenience of expanding MLT studies until 09:00 h when differences between morning type and evening type subjects may still be found.

Summer/winter changes in serum S100B protein concentration as a source of research variance.

BACKGROUND: S100B is a calcium binding protein that can be measured in cerebral and extra cerebral biological tissues and fluids. Circadian and seasonal variations have been described in several biological molecules such as melatonin, cortisol and testosterone. Healthy subjects do not have a circadian rhythm of S100B. There is no information on seasonal variations of S100B levels. The aim of this research is to study whether healthy subjects present summer/winter changes in serum S100B protein concentrations. METHODS: Ninety-eight subjects were studied in summer, of those, 64 participated in the winter evaluation. Blood was drawn by venipuncture at 09:00 h, 12:00 h and 00:00 h in summer and winter. Serum was separated from blood by centrifugation and stored at -70° until analysis. Serum S100B concentrations were measured by ELISA. RESULTS: Serum S100B concentrations were significantly higher in summer than winter (09:00 h: 43.4 ± 24.6 ng/ml vs. 29.3 ± 22.7 ng/ml, p < 0.001; 12:00 h: 42.8 ± 25.0 ng/ml vs. 23.0 ± 22.1 ng/ml, p < 0.001; 00:00 h: 44.5 ± 23.2 ng/ml vs. 28.5 ± 24.6 ng/ml, p < 0.001). Age, gender, body mass index and time points when blood was extracted did not affect serum S100B concentrations neither in summer nor in winter. CONCLUSIONS: Our results point to the fact that there is an important difference in serum S100B concentrations between summer and winter. It is strongly advisable to consider this summer/winter difference in serum S100B concentrations when researching into this area.

S100B and schizophrenia.

The research for peripheral biological markers of schizophrenia, although abundant, has been unfruitful. In the last 2 decades, the S100B protein has made its own room in this area of research. S100B is a calcium-binding protein that has been proposed as a marker of astrocyte activation and brain dysfunction. Research results on S100B concentrations and schizophrenia clinical diagnosis are very consistent; patients with schizophrenia have higher S100B concentrations than healthy controls. The results regarding schizophrenia subtypes and clinical characteristics are not as conclusive. Age of patients, body mass index, illness duration and age at onset have been found to show no correlation, a positive correlation or a negative correlation with S100B levels. With respect to psychopathology, S100B data are inconclusive. Positive, negative and absence of correlation between S100B concentrations and positive and negative psychopathology have been reported. Methodological biases, such as day/night and seasonal variations, the use of anticoagulants to treat biological samples, the type of analytical technique to measure S100B and the different psychopathological scales to measure schizophrenia symptoms, are some of the factors that should be taken into account when researching into this area in order to reduce the variability of the reported results. The clinical implications of S100B changes in schizophrenia remain to be elucidated.